MarketCapExport financials
iCAD (ICAD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
iCAD Income Statement 2024-2008 | ICAD
Brief overview of income trends at iCAD
The comparison covers a five-year financial horizon. According to figures from iCAD, revenue changed from $31.3 million to $19.6 million over five years. Overall revenue changed by −37.4%, equal to an annualized rate of about −9%. Sales followed a declining trajectory over the five years.
The five-year change in gross profit reached −31.3%: from 24.2 million dollars to 16.6 million dollars. Direct costs grew more slowly than revenue and improved the economics of sales. Gross profit as a share of revenue changed from 77.3% to 84.8%. A wider margin shows that the economics of the core business improved.
EBITDA changed from −6.1 million dollars to −6 million dollars (+1.6%). Additional revenue translated efficiently into EBITDA. EBITDA margin was −19.5% at the start and −30.7% at the end. The business retained less EBITDA from each unit of revenue.
The net financial result changed from −$13.6 million to −$5.6 million. Losses became smaller, but the business remains unprofitable.
The five-year change in capitalization reached −65.8%: from $159 million to $54.3 million. Investors remain cautious despite better financial results.
Summary assessment
The financial trajectory is weak and requires a cautious interpretation. The strongest signals are improving net profitability and better sales economics. The overall view is constrained by a weaker market valuation, a low EBITDA margin and limited revenue growth. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement iCAD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
54.3 M | 41.2 M | 32.8 M | 120 M | 409 M | 159 M | 93.3 M | 52 M | 59.6 M | 70.9 M | 112 M | 126 M | 53.1 M | 30 M | - | - | - |
Shares |
26.4 M | 25.6 M | 25.2 M | 24.8 M | 22.1 M | 18.4 M | 16.7 M | 16.3 M | 15.9 M | 15.7 M | 14.1 M | 10.8 M | 10.8 M | 10.9 M | 9.17 M | 45.5 M | - |
Historical Prices |
2.06 | 1.61 | 1.3 | 4.83 | 18.5 | 13.3 | 5.13 | 3.43 | 3.76 | 4.47 | 9.94 | 11.7 | 5.45 | 2.55 | - | - | - |
Net Income |
-5.62 M | -4.85 M | -13.7 M | -11.2 M | -17.6 M | -13.6 M | -9.02 M | -14.3 M | -10.1 M | -32.4 M | -1.01 M | -7.61 M | -9.37 M | -37.6 M | -6.22 M | -1.97 M | - |
Revenue |
19.6 M | 17.3 M | 19.8 M | 33.6 M | 29.7 M | 31.3 M | 25.6 M | 28.1 M | 26.3 M | 41.6 M | 43.9 M | 33.1 M | 28.3 M | 28.7 M | - | - | - |
Cost of Revenue |
2.97 M | 2.53 M | 2.98 M | 9.4 M | 8.34 M | 7.11 M | 6.19 M | 9.93 M | 7.82 M | 12.2 M | 12.7 M | 9.98 M | 8.24 M | 8.62 M | 4.88 M | 6.3 M | - |
Gross Profit |
16.6 M | 14.8 M | 16.8 M | 24.2 M | 21.4 M | 24.2 M | 19.4 M | 18.2 M | 18.5 M | 29.4 M | 31.2 M | 23.1 M | 20 M | 20 M | 19.7 M | 21.8 M | - |
Operating Income |
-6.27 M | -7.69 M | -10.2 M | -10.7 M | -9.39 M | -6.4 M | -8.13 M | -14.2 M | -9.97 M | -30.1 M | 815 K | -1.78 M | -5.41 M | -37.1 M | -6.54 M | -2.12 M | - |
Interest Expense |
-49 K | -14 K | 10 K | 141 K | 476 K | 784 K | 504 K | 124 K | 63 K | 650 K | 2.64 M | 3.28 M | 3.42 M | 422 K | 348 K | 9 K | - |
EBITDA |
-6.03 M | -7.44 M | -9.98 M | -10.5 M | -9.19 M | -6.12 M | -7.82 M | -9.53 M | -8.85 M | -1 M | 2.56 M | -838 K | -2.62 M | -7.19 M | -6.07 M | -1.37 M | - |
Operating Expenses |
22.9 M | 22.5 M | 27 M | 35 M | 30.7 M | 30.6 M | 27.6 M | 28.2 M | 28.5 M | 32 M | 30.4 M | 24.9 M | 25.4 M | 30.4 M | 26.2 M | 23.9 M | - |
General and Administrative Expenses |
7.63 M | 9.32 M | 10.5 M | 10.4 M | 9.12 M | 7.44 M | 9.12 M | 7.88 M | 7.68 M | 8.79 M | 8.04 M | 6.74 M | 6.97 M | 10.1 M | 9.89 M | 7.35 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement iCAD
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
26.7 M | 26.4 M | 26.4 M | 26.4 K | 26.4 M | 26.4 M | 25.6 M | 25.3 K | 25.3 K | 25.3 M | 25.2 M | 25.2 M | 25.2 K | 25.1 M | 25.1 M | 25 M | 23.9 M | 23.5 M | 23.2 M | 22.4 M | 20.2 M | 19.3 M | 19.3 M | 17.6 M | 17.2 M | 16.8 M | 16.7 M | 16.7 M | 16.6 M | 16.5 M | 16.4 M | 16.3 M | 16.1 M | 16 M | 16 M | 15.9 M | 15.8 M | 15.7 M | 15.7 M | 15.7 M | 15.6 M | 15.5 M | 15.3 M | 14.1 M | 11.4 M | 10.9 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.8 K | 10.9 M | 10.9 K | 54.6 K | 10.9 M |
Net Income |
-833 K | - | -1.8 M | -1.74 M | -1.22 M | - | -1.37 M | -1.75 M | -3.78 M | - | -3.9 M | -3.12 M | -3.54 M | - | -2.18 M | -3.28 M | -1.64 M | - | -1.8 M | -2.4 M | -11.8 M | -3.35 M | -2.96 M | -3.53 M | -3.72 M | -3.34 M | -1.36 M | -1.03 M | -3.28 M | -4.24 M | -6.93 M | -2.63 M | -457 K | -3.32 M | -2.68 M | -1.58 M | -2.53 M | -2.4 M | -402 K | -27.8 M | -1.86 M | -96 K | 274 K | -997 K | -190 K | -4.41 M | -589 K | -1.88 M | -727 K | -2.7 M | -1.46 M | -2.94 M | -2.26 M | -2.23 M | -25.6 M | -5.41 M | -4.31 M |
Revenue |
4.87 M | - | 4.22 M | 5.03 M | 4.95 M | - | 4.07 M | 4.17 M | 5.78 M | - | 6.36 M | 7.58 M | 7.52 M | - | 9.36 M | 7.83 M | 8.64 M | - | 7.13 M | 5.57 M | 6.55 M | 9.38 M | 7.86 M | 7.33 M | 6.77 M | 6.95 M | 6.19 M | 6.16 M | 6.31 M | 7.9 M | 7 M | 6.41 M | 6.79 M | 6.93 M | 6 M | 7.37 M | 6.04 M | 7.61 M | 9.58 M | 11.1 M | 13.2 M | 13.2 M | 12.6 M | 9.67 M | 8.52 M | 9.14 M | 8.29 M | 7.71 M | 7.93 M | 7.82 M | 8.18 M | 5.93 M | 6.34 M | 6.61 M | 8.05 M | 6.65 M | 7.34 M |
Cost of Revenue |
685 K | - | 583 K | 812 K | 841 K | - | 552 K | 773 K | 1.65 M | - | 1.98 M | 2.08 M | 2.21 M | - | 2.65 M | 2.29 M | 2.36 M | - | 2.1 M | 1.21 M | 2.04 M | - | 1.8 M | 1.6 M | 1.49 M | - | 1.45 M | 1.38 M | 1.82 M | - | 2.36 M | 1.91 M | 2.1 M | - | 1.9 M | 1.67 M | 1.85 M | - | 2.76 M | 3.26 M | 3.86 M | - | 3.4 M | 2.84 M | 2.59 M | - | 2.36 M | 2.49 M | 2.28 M | - | 2.3 M | 1.76 M | 1.92 M | - | 2.16 M | 2.14 M | 2.21 M |
Gross Profit |
4.19 M | - | 3.63 M | 4.22 M | 4.11 M | - | 3.52 M | 3.4 M | 4.13 M | - | 4.37 M | 5.49 M | 5.31 M | - | 6.71 M | 5.54 M | 6.29 M | - | 5.02 M | 4.36 M | 4.51 M | 7.16 M | 6.05 M | 5.73 M | 5.28 M | 5.41 M | 4.74 M | 4.78 M | 4.5 M | 4.34 M | 4.64 M | 4.5 M | 4.69 M | 4.53 M | 4.1 M | 5.7 M | 4.19 M | 5.29 M | 6.82 M | 7.88 M | 9.36 M | 9.3 M | 9.17 M | 6.83 M | 5.93 M | 6.29 M | 5.93 M | 5.22 M | 5.65 M | 5.55 M | 5.88 M | 4.17 M | 4.43 M | 4.5 M | 5.89 M | 4.5 M | 5.13 M |
Operating Income |
-1.13 M | - | -2.02 M | -1.95 M | -1.44 M | - | -1.22 M | -2.51 M | -3.92 M | - | -3.96 M | -3.11 M | -3.52 M | - | -2.18 M | -2.87 M | -1.53 M | - | -1.69 M | -2.31 M | -3.89 M | - | -1.96 M | -1.46 M | -1.03 M | - | -1.25 M | -939 K | -3.15 M | - | -6.94 M | -2.62 M | -435 K | - | -2.65 M | -1.53 M | -2.49 M | - | -344 K | -27.8 M | 443 K | - | 926 K | -166 K | -460 K | - | -354 K | -473 K | -328 K | - | -704 K | -1.9 M | -2.03 M | - | -25.5 M | -5.31 M | -4.22 M |
Interest Expense |
124 K | - | 10 K | 11 K | 20 K | - | - | -3 K | - | - | 7 K | - | 9 K | - | - | 29 K | 112 K | - | 115 K | 115 K | 130 K | - | 193 K | 202 K | 209 K | - | 118 K | 113 K | 142 K | - | 36 K | 10 K | 5 K | - | 15 K | 21 K | 23 K | - | 46 K | 70 K | 507 K | - | 647 K | 614 K | 817 K | - | 807 K | 834 K | 826 K | - | 883 K | 831 K | 835 K | - | 111 K | 111 K | 105 K |
EBITDA |
-1.07 M | - | -1.96 M | -1.88 M | -1.38 M | - | -1.16 M | -2.44 M | -3.87 M | - | -3.9 M | -3.05 M | -3.46 M | - | -2.12 M | -2.81 M | -1.48 M | - | -1.64 M | -2.26 M | -3.84 M | - | -1.89 M | -1.39 M | -964 K | - | -1.18 M | -862 K | -3.06 M | - | -6.84 M | -2.51 M | -313 K | - | -2.36 M | -1.24 M | -2.21 M | - | -87 K | -27.3 M | 1.06 M | - | 1.35 M | 89 K | -209 K | - | -76 K | -108 K | -145 K | - | -3 K | -1.43 M | -1.78 M | - | -24.7 M | -4.76 M | -3.92 M |
Operating Expenses |
5.32 M | - | 5.65 M | 6.16 M | 5.55 M | - | 4.74 M | 5.91 M | 8.06 M | - | 8.33 M | 8.6 M | 8.83 M | - | 8.89 M | 8.41 M | 7.82 M | - | 6.71 M | 6.67 M | 8.4 M | - | 8.01 M | 7.18 M | 6.32 M | - | 5.99 M | 5.72 M | 7.65 M | - | 11.6 M | 7.13 M | 5.12 M | - | 6.75 M | 7.24 M | 6.68 M | - | 7.16 M | 35.7 M | 8.92 M | - | 8.24 M | 7 M | 6.39 M | - | 6.28 M | 5.7 M | 5.98 M | - | 6.59 M | 6.07 M | 6.45 M | - | 31.4 M | 9.81 M | 9.35 M |
General and Administrative Expenses |
2.25 M | - | 1.81 M | 2.07 M | 1.9 M | - | 2.04 M | 2.76 M | 2.86 M | - | 2.67 M | 2.74 M | 2.93 M | - | 2.66 M | 2.65 M | 2.15 M | - | 1.83 M | 2.11 M | 2.53 M | - | 1.87 M | 1.86 M | 1.55 M | - | 1.78 M | 1.58 M | 2.06 M | - | 1.94 M | 2.09 M | 2.03 M | - | 1.78 M | 2.18 M | 1.63 M | - | 2.12 M | 2.33 M | 2.21 M | - | 2.28 M | 1.86 M | 1.69 M | - | 1.46 M | 1.6 M | 1.67 M | - | 1.77 M | 1.6 M | 1.6 M | - | 2.15 M | 3.41 M | 2.8 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company iCAD (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
American Well Corporation
AMWL
|
$ 13.97 | 5.91 % | $ 224 M |  USA |
 |
Evolent Health
EVH
|
$ 4.83 | -0.82 % | $ 552 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Omnicell
OMCL
|
$ 36.34 | -0.41 % | $ 1.67 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.37 | 4.93 % | $ 174 M | USA |
 |
Phreesia
PHR
|
$ 12.26 | 1.78 % | $ 732 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.57 | 1.42 % | $ 1.27 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.74 | -0.57 % | $ 122 M | USA |
 |
So-Young International
SY
|
$ 2.19 | -3.1 % | $ 171 M |  China |
 |
Teladoc Health
TDOC
|
$ 6.3 | 1.45 % | $ 1.11 B | USA |
 |
HealthEquity
HQY
|
$ 97.88 | 1.33 % | $ 8.43 B | USA |
 |
Veeva Systems
VEEV
|
$ 320.55 | 0.59 % | $ 52.5 B | USA |
 |
Schrödinger
SDGR
|
$ 23.9 | 2.14 % | $ 1.76 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.34 | -4.96 % | $ 4.58 M | China |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 33.51 | -0.77 % | $ 1.01 B | USA |
 |
Progyny
PGNY
|
$ 28.44 | -0.49 % | $ 2.42 B | USA |
 |
10x Genomics
TXG
|
$ 75.59 | 5.78 % | $ 9.43 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |